| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | — | — |
| Cost of Revenue | $1.1M | — | — |
| R&D Expense | $0 | — | -100.0% |
| SG&A Expense | $45.0M | — | +304.6% |
| Operating Income | -$44.1M | — | -160.7% |
| Net Income | -$41.5M | — | -183.8% |
| EPS (Basic) | -$1.32 | — | -149.1% |
| EPS (Diluted) | -$1.32 | — | -149.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $24.8M | -1.6% | +7.5% |
| Accounts Receivable | $343K | +4.3% | — |
| Inventory | $3.5M | +19.1% | — |
| Current Assets | $268.4M | -11.0% | +35.6% |
| Total Assets | $272.5M | -10.9% | +35.4% |
| Current Liabilities | $25.8M | +21.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$33.6M | — | -109.2% |
| Capital Expenditures | $18K | — | -83.6% |
| Investing Cash Flow | $33.2M | — | +75.6% |
| Financing Cash Flow | $14K | — | -68.2% |
| Free Cash Flow | -$33.6M | — | -107.9% |
| +201.2% |
| Total Liabilities | $26.0M | +20.9% | +181.8% |
| Stockholders' Equity | $246.5M | -13.3% | +28.4% |